BridgeBio Oncology Therapeutics Inc. (BBOT) 10-Year Financial Performance & Capital Metrics

BBOT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutBridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.Show more

Revenue $0
EBITDA -$81M -24.7%
Net Income -$74M -14.8%
EPS (Diluted) 0.46 +23100.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -78.74%
ROIC -64.85% +100.0%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 18.8% through buybacks
✓Trading at only 1.1x book value

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-110.39%

EPS CAGR

10Y-

5Y-

3Y-

TTM-839.87%

ROCE

10Y Avg-116715.66%

5Y Avg-116715.66%

3Y Avg-116715.66%

Latest-83.29%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.55B	7.62	54.43	55.85%	3.98%	15.63%	0.35%	1.02
EXELExelixis, Inc.	12.13B	45.23	25.70	18.49%	29.63%	31.37%	5.23%	0.09
INBXInhibrx Biosciences, Inc.	1.1B	75.93	0.65	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.16B	6.31	-2.99		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.4B	8.07	-3.42	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.1B	11.25	-6.15			-33.24%		0.01
ZLABZai Lab Limited	2.17B	19.61	-7.54	49.59%	-46.83%	-27.21%		0.18
TNGXTango Therapeutics, Inc.	1.67B	12.39	-10.41	15.17%	-151.15%	-62.81%		0.18

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	0
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	43.36K	3.52K	64.77M	80.86M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	43.36K	3.52K	8.48M	7.76M
SG&A % of Revenue	-	-	-	-
Research & Development	0	0	56.29M	73.11M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	0	0
Operating Income+	-43.36K	-3.52K	-64.77M	-80.86M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	0.92%	-18399.85%	-0.25%
EBITDA+	-43.36K	-3.52K	-64.68M	-80.66M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	0.92%	-18373.72%	-0.25%
D&A (Non-Cash Add-back)	0	0	92K	208K
EBIT	-43.36K	-3.52K	-64.77M	-80.86M
Net Interest Income+	0	0	0	8.46M
Interest Income	0	0	0	8.46M
Interest Expense	0	0	0	0
Other Income/Expense	0	0	72K	6.59M
Pretax Income+	-43.36K	-3.52K	-64.7M	-74.28M
Pretax Margin %	-	-	-	-
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-43.36K	-3.52K	-64.7M	-74.28M
Net Margin %	-	-	-	-
Net Income Growth %	-	0.92%	-18379.4%	-0.15%
Net Income (Continuing)	-43.36K	-3.52K	-64.7M	-74.28M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.00	0.00	-0.00	0.46
EPS Growth %	-	-	-	-
EPS (Basic)	-0.00	0.00	-0.00	0.46
Diluted Shares Outstanding	20.48M	20.48M	20.48M	16.64M
Basic Shares Outstanding	20.48M	20.48M	20.48M	16.64M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	0	0	0	1.95M
Cash & Short-Term Investments	0	0	0	1.7M
Cash Only	0	0	0	1.7M
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	0
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	0	0	0	0
Total Non-Current Assets+	144.28K	144.58K	332.89K	192.47M
Property, Plant & Equipment	0	0	0	0
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	0	0	0	192.45M
Other Non-Current Assets	144.28K	144.58K	332.89K	25.13K
Total Assets+	144.28K	144.58K	332.89K	194.42M
Asset Turnover	-	-	-	-
Asset Growth %	-	0%	1.3%	583.04%
Total Current Liabilities+	162.64K	166.46K	396.46K	187.51K
Accounts Payable	0	0	0	0
Days Payables Outstanding	-	-	-	-
Short-Term Debt	36.96K	43.11K	70.09K	0
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	0	0	0	0
Current Ratio	-	-	-	10.40x
Quick Ratio	-	-	-	10.40x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	0	0	0	5.52M
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	5.52M
Total Liabilities	162.64K	166.46K	396.46K	5.71M
Total Debt+	36.96K	43.11K	70.09K	0
Net Debt	36.96K	43.11K	70.09K	-1.7M
Debt / Equity	-	-	-	-
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-	-	-	-
Total Equity+	-18.36K	-21.88K	-63.57K	188.72M
Equity Growth %	-	-0.19%	-1.91%	2969.69%
Book Value per Share	-0.00	-0.00	-0.00	11.34
Total Shareholders' Equity	-18.36K	-21.88K	-63.57K	188.72M
Common Stock	288	288	460	192.45M
Retained Earnings	-43.36K	-46.88K	-88.57K	-3.73M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	0	0	0	-763.82K
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	-	-	-
Net Income	-74	-3.52K	-41.69K	7.6M
Depreciation & Amortization	0	0	0	0
Stock-Based Compensation	0	0	0	271.57K
Deferred Taxes	0	0	0	0
Other Non-Cash Items	74	3.52K	26.69K	-8.53M
Working Capital Changes	0	0	15K	-104.61K
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	0	0	0	172.51K
Cash from Investing+	0	0	0	-184M
Capital Expenditures	0	0	0	0
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	0
Cash from Financing+	0	0	0	186.46M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	0	0	-578.55K
Net Change in Cash	-	-	-	-
Free Cash Flow+	0	0	0	-763.82K
FCF Margin %	-	-	-	-
FCF Growth %	-	-	-	-
FCF per Share	-	-	-	-0.05
FCF Conversion (FCF/Net Income)	-	-	-	0.01x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-78.74%
Return on Invested Capital (ROIC)	-	-13.26%	-350050.44%	-64.85%
FCF Conversion	-	-	-	0.01x

Frequently Asked Questions

Valuation & Price

BridgeBio Oncology Therapeutics Inc. (BBOT) has a price-to-earnings (P/E) ratio of 26.2x. This suggests investors expect higher future growth.

Growth & Financials

BridgeBio Oncology Therapeutics Inc. (BBOT) grew revenue by 0.0% over the past year. Growth has been modest.

BridgeBio Oncology Therapeutics Inc. (BBOT) reported a net loss of $114.9M for fiscal year 2024.

Dividend & Returns

BridgeBio Oncology Therapeutics Inc. (BBOT) has a return on equity (ROE) of -78.7%. Negative ROE indicates the company is unprofitable.

BridgeBio Oncology Therapeutics Inc. (BBOT) had negative free cash flow of $95.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener